Montelukast (Singulair) Side Effects Support and Discussion Group FDA Speech

Tue, 26 Aug 2025 15:06:41 +0000

On September 27, 2019 the FDA Pediatric Advisory Committee reviewed the safety of the widely prescribed medication Montelukast due to the continuously reported neuropsychiatric side effects. Kammy Pany spoke on behalf of the then 7,300 members who have suffered and are looking for a black box warning, medication guide and a Risk Evaluation and Mitigation strategy for safer use of this medication.